IPF
Clinical trials for IPF explained in plain language.
Never miss a new study
Get alerted when new IPF trials appear
Sign up with your email to follow new studies for IPF, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New IPF drug passes first safety check in small trial
Disease control CompletedThis study tested an experimental drug called PMG1015 in 29 people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and makes breathing hard. The main goal was to see if the drug is safe and how the body handles it. Participants received eithe…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Pulmongene Ltd. • Aim: Disease control
Last updated May 17, 2026 05:35 UTC
-
New pill targets immune cells to fight lung scarring
Disease control CompletedThis study tested an oral drug called GRI-0621 in 35 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. The drug aims to reduce scarring by blocking certain immune cells (NKT1 cells). Participants took either the drug or a…
Matched conditions: IPF
Phase: PHASE2 • Sponsor: GRI Bio Operations, Inc. • Aim: Disease control
Last updated May 17, 2026 05:28 UTC
-
New drug shows promise for lung scarring disease in small trial
Disease control CompletedThis study tested an experimental drug called MN-001 in 15 people with moderate to severe idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. For 6 months, some participants received the drug and others received a placebo (a dummy pill…
Matched conditions: IPF
Phase: PHASE2 • Sponsor: MediciNova • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Simple questions could revolutionize palliative care for lung disease patients
Knowledge-focused CompletedThis study tested a new questionnaire to help doctors quickly identify the right level of palliative care for people newly diagnosed with idiopathic pulmonary fibrosis (IPF). Thirty patients answered a few simple questions, and their answers were compared to expert doctor assessm…
Matched conditions: IPF
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated May 17, 2026 05:35 UTC
-
New drug for lung scarring passes first safety check in healthy people
Knowledge-focused CompletedThis early-stage study tested a single dose of an experimental drug called HLX6018 in 66 healthy adults to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. No treatment was given…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Shanghai Henlius Biotech • Aim: Knowledge-focused
Last updated May 17, 2026 05:27 UTC
-
Which score best predicts lung disease survival? new study compares three tools
Knowledge-focused CompletedThis study looked back at 143 patients with two types of lung scarring diseases (IPF and hypersensitivity pneumonitis) to see how well three different scoring systems predict survival. Researchers compared the GAP, ILD-GAP, and CPI scores using patient records. The goal was to fi…
Matched conditions: IPF
Sponsor: Saglik Bilimleri Universitesi • Aim: Knowledge-focused
Last updated May 08, 2026 12:03 UTC